BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36651960)

  • 1. A comparative analysis of treatment efficacy in intermediate-risk thyroid cancer.
    Abiri A; Nguyen T; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
    Eur Arch Otorhinolaryngol; 2023 May; 280(5):2525-2533. PubMed ID: 36651960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and Trends of Treatments in High-Risk Differentiated Thyroid Cancer.
    Abiri A; Goshtasbi K; Torabi SJ; Kuan EC; Armstrong WB; Tjoa T; Haidar YM
    Otolaryngol Head Neck Surg; 2023 Apr; 168(4):745-753. PubMed ID: 35471863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Survival Outcomes Following Postsurgical Radioactive Iodine Versus External Beam Radiation in Stage IV Differentiated Thyroid Carcinoma.
    Yang Z; Flores J; Katz S; Nathan CA; Mehta V
    Thyroid; 2017 Jul; 27(7):944-952. PubMed ID: 28446057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012.
    Carhill AA; Litofsky DR; Ross DS; Jonklaas J; Cooper DS; Brierley JD; Ladenson PW; Ain KB; Fein HG; Haugen BR; Magner J; Skarulis MC; Steward DL; Xing M; Maxon HR; Sherman SI
    J Clin Endocrinol Metab; 2015 Sep; 100(9):3270-9. PubMed ID: 26171797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiated Thyroid Cancer lymph-node relapse. Role of adjuvant radioactive iodine therapy after lymphadenectomy.
    Piccardo A; Puntoni M; Bottoni G; Treglia G; Foppiani L; Bertoli M; Catrambone U; Arlandini A; Dib B; Altrinetti V; Massollo M; Bossert I; Cabria M; Bertagna F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):926-934. PubMed ID: 27966046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 7. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Timing of Adjuvant Radioactive Iodine Therapy Does Not Affect Overall Survival in Low- and Intermediate-Risk Papillary Thyroid Carcinoma.
    Suman P; Wang CH; Moo-Young TA; Prinz RA; Winchester DJ
    Am Surg; 2016 Sep; 82(9):807-14. PubMed ID: 27670568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of adjuvant radioactive iodine therapy with survival in node-positive papillary thyroid cancer.
    Sun Y; Gong J; Guo B; Shang J; Cheng Y; Xu H
    Oral Oncol; 2018 Dec; 87():152-157. PubMed ID: 30527231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative radioactive iodine-131 ablation is not necessary among patients with intermediate-risk differentiated thyroid carcinoma: a population-based study.
    Zhang H; Cai Y; Zheng L; Zhang Z; Jiang N
    Hell J Nucl Med; 2017; 20(1):3-10. PubMed ID: 28315902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
    Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
    Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumor infiltration (stage pT4).
    Farahati J; Reiners C; Stuschke M; Müller SP; Stüben G; Sauerwein W; Sack H
    Cancer; 1996 Jan; 77(1):172-80. PubMed ID: 8630926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphovascular invasion is associated with survival for papillary thyroid cancer.
    Pontius LN; Youngwirth LM; Thomas SM; Scheri RP; Roman SA; Sosa JA
    Endocr Relat Cancer; 2016 Jul; 23(7):555-62. PubMed ID: 27317633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse-free survival after adjuvant radioactive iodine therapy in patients with differentiated thyroid carcinoma with a microscopically positive tumor margin.
    Watanabe K; Igarashi T; Uchiyama M; Ojiri H
    Ann Nucl Med; 2020 Dec; 34(12):920-925. PubMed ID: 32940889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DEATH RELATED TO PULMONARY METASTASIS IN PATIENTS WITH DIFFERENTIATED THYROID CANCER.
    Leite AK; Kulcsar MA; de Godoi Cavalheiro B; de Mello ES; Alves VA; Cernea CR; Matos LL
    Endocr Pract; 2017 Jan; 23(1):72-78. PubMed ID: 27749128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.